FDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset CTx-1301

Details of the FDA's minutes include the following, all of which will be a matter of review during the approval process: About Attention Deficit/Hyperactivity Disorder (ADHD) ADHD is a chronic neurobiological and developmental disorder that affects millions of children and often continues into adulthood. The condition is marked by an ongoing pattern of inattention and/or hyperactivity- impulsivity that interferes with functioning or development. In the U.S., over 20 million patients have been diagnosed with ...